Review summarizes molecular pathways and treatment options for Adult T-cell leukemia/lymphoma

This systematic review article synthesizes existing evidence on the molecular pathogenesis and treatment approaches for Adult T-cell leukemia/lymphoma (ATLL). The review describes ATLL as associated with poor clinical outcomes and identifies frequent mutations in TCR/NF-κB, JAK/STAT, and apoptotic pathways. It does not report new primary data, specific sample sizes, study settings, or follow-up durations.

The review summarizes three main treatment modalities: mogamulizumab, antiviral therapies, and allogeneic hematopoietic stem cell transplantation (allo-HSCT). For mogamulizumab, the review states it has demonstrated clinical efficacy in relapsed settings, but provides no specific effect sizes, absolute numbers, confidence intervals, or p-values to quantify this finding. No comparator treatments are reported for any intervention.

No safety, tolerability, or adverse event data for any intervention are reported in this review. The authors note that antiviral therapies and allo-HSCT are considered treatment pillars for selected patients, but do not specify selection criteria or comparative effectiveness. Key limitations stem from the review's nature: it summarizes findings from other studies without providing new quantitative evidence. The certainty of the evidence statements is therefore limited by the quality and completeness of the original studies being summarized.

For clinical practice, this review provides a high-level overview of the current ATLL treatment landscape and molecular understanding. However, its utility for guiding specific treatment decisions is constrained by the lack of reported efficacy metrics, safety profiles, and direct comparisons between therapies. Clinicians should interpret the efficacy statements about mogamulizumab as summaries of prior research findings rather than new evidence.